Attenuation of tumor growth by formation of antiproliferative glycosaminoglycans correlates with low acetylation of histone H3

Cancer Research

Volumn 70, Issue 9, 2010, Pages 3771-3779

  Nilsson, Ulrika ^a,b   Johnsson, Richard ^b   Fransson, Lars Åke ^a   Ellervik, Ulf ^b   Mani, Katrin ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEXTRO XYLOPYRANOSIDE; GLYCOSAMINOGLYCAN; HISTONE H3; PYRANOSIDE; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BIOSYNTHESIS; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER GROWTH; CARCINOMA CELL; CELL NUCLEUS; CELLULAR DISTRIBUTION; COCULTURE; CONTROLLED STUDY; FEMALE; GLIOMA CELL; GROWTH RETARDATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR CELL;

ACETYLATION; ANIMALS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL NUCLEUS; FEMALE; GLIOMA; GLYCOSAMINOGLYCANS; GLYCOSIDES; HISTONES; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASMS; RATS; URINARY BLADDER NEOPLASMS;

EID: 77951741986     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4331     Document Type: Article

References (32)

1. Yip GW, Smollich M, Götte M. Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther 2006;5:2139-2148
2. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005;5:526-542
3. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002;2:521-528
4. Munshi A, Shafi G, Aliya N, Jyothy A. Histone modifications dictate specific biological readouts. J Genet Genomics 2009;36:75-88.
5. Hsia E, Richardson TP, Nugent MA. Nuclear localization of basic fibroblast growth factor is mediated by heparan sulfate proteoglycans through protein kinase C signaling. J Cell Biochem 2003;88: 1214-1225
6. Ishihara M, Fedarko NS, Conrad HE. Transport of heparan sulfate into the nuclei of hepatocytes. J Biol Chem 1986;261:13575-13580
7. Watson K, Gooderham NJ, Davies DS, Edwards RJ. Nucleosomes bind to cell surface proteoglycans. J Biol Chem 1999;274:21707-21713
8. Buczek-Thomas JA, Hsia E, Rich CB, Foster JA, Nugent MA. Inhibition of histone acetyltransferase by glycosaminoglycans. J Cell Biochem 2008;105:108-120
9. NCI. Standard therapy with or without dalteparin in treating patients with advanced breast, lung, colorectal, or prostate cancer. NCI 2009; Clinical Trial Identifier, last updated: August 19, 2009.
10. GlaxoSmithKline. Effects of nadroparin in patients with lung, pancreas or prostate cancer. GlaxoSmithKline 2008;Clinical Trial Identifier: NCT00312013.
11. Schwartz NB, Galligani L, Ho PL, Dorfman A. Stimulation of synthesis of free chondroitin sulfate chains by β-D-xylosides in cultured cells. Proc Natl Acad Sci U S A 1974;71:4047-4051
12. Masson PJ, Coup D, Millet J, Brown NL. The effect of the β-D-xyloside naroparcil on circulating plasma glycosaminoglycans. An explanation for its known antithrombotic activity in the rabbit. J Biol Chem 1995; 270:2662-2668
13. Sobue M, Habuchi H, Ito K, et al. β-D-Xylosides and their analogues as artificial initiators of glycosaminoglycan chain synthesis. Aglycone-related variation in their effectiveness in vitro and in ovo. Biochem J 1987;241:591-601.
14. Kolset SO, Sakurai K, Ivhed I, Overvatn A, Suzuki S. The effect of β-D-xylosides on the proliferation and proteoglycan biosynthesis of monoblastic U-937 cells. Biochem J 1990;265:637-645 (Pubitemid 20053864)
15. Mani K, Havsmark B, Persson S, et al. Heparan/chondroitin/dermatan sulfate primer 2-(6-hydroxynaphthyl)-O-β-D-xylopyranoside preferentially inhibits growth of transformed cells. Cancer Res 1998; 58:1099-1104
16. Sutton A, Friand V, Papy-Garcia D, et al. Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells. Mol Cancer Ther 2007;6:2948-2958
17. Ben-Zaken O, Tzaban S, Tal Y, et al. Cellular heparan sulfate participates in the metabolism of prions. J Biol Chem 2003;278: 40041-40049 (Pubitemid 37248570)
18. Sok J, Pineau N, Dalko-Csiba M, Breton L, Bernerd F. Improvement of the dermal epidermal junction in human reconstructed skin by a new c-xylopyranoside derivative. Eur J Dermatol 2008;18:297-302. (Pubitemid 351821233)
19. Rolls A, Shechter R, London A, et al. Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in microglia/macrophage activation. PLoS Med 2008;5:e171.
20. Mani K, Belting M, Ellervik U, et al. Tumor attenuation by 2(6-hydroxynaphthyl)-β-D-xylopyranoside requires priming of heparan sulfate and nuclear targeting of the products. Glycobiology 2004; 14:387-397 (Pubitemid 38750143)
21. Jacobsson M, Ellervik U, Belting M, Mani K. Selective antiproliferative activity of hydroxynaphthyl-β-D-xylosides. J Med Chem 2006;49: 1932-1938
22. Cheng F, Johnsson R, Nilsson J, Fransson LÅ, Ellervik U, Mani K. Potentiation of naphthoxyloside cytotoxicity on human tumor cells by difluoromethylornithine and spermine-NONOate. Cancer Lett 2009;273:148-154
23. Mani K, Cheng F, Fransson LÅ. Heparan sulfate degradation products can associate with oxidized proteins and proteasomes. J Biol Chem 2007;282:21934-21944 (Pubitemid 47201817)
24. Esko JD, Fritz TA. Primers of heparan sulfate biosynthesis. PCT Patent 1994, March 17: WO 94/05678.
25. Johnsson R, Mani K, Ellervik U. Evaluation of fluorescently labeled xylopyranosides as probes for proteoglycan biosynthesis. Bioorg Med Chem Lett 2007;17:2338-2341 (Pubitemid 46501763)
26. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009;8:1409-1420
27. Fritz TA, Lugemwa FN, Sarkar AK, Esko JD. Biosynthesis of heparan sulfate on β-D-xylosides depends on aglycone structure. J Biol Chem 1994;269:300-307.
28. Victor XV, Nguyen TK, Ethirajan M, Nguyen KV, Kuberan B. Investigating the elusive mechanism of glycosaminoglycan biosynthesis. J Biol Chem 2009;284:25842-25853
29. Chen L, Sanderson RD. Heparanase regulates levels of syndecan-1 in the nucleus. PLoS One 2009;4:e4947.
30. Zong F, Fthenou E, Wolmer N, et al. Syndecan-1 and FGF-2, but not FGF receptor-1, share a common transport route and co-localize with heparanase in the nuclei of mesenchymal tumor cells. PLoS One 2009;4:e7346.
31. Götte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 2006;66:10233-10237 (Pubitemid 44799736)
32. Fukuda H, Sano N, Muto S, Horikoshi M. Simple histone acetylation plays a complex role in the regulation of gene expression. Brief Funct Genomic Proteomic 2006;5:190-208. (Pubitemid 46470220)